CombiMatrix Presents Preliminary Data on Comprehensive Cancer Array Test | GenomeWeb

An investigational microarray test that measures miRNA expression patterns to detect the presence of cancer and distinguish between cancers has yielded promising preliminary data, according to CombiMatrix.

The company presented data at the Cambridge Healthtech Institute's Molecular Medicine Tri-Conference in San Francisco last week that showed that its so-called Comprehensive Cancer Array can detect "dramatically different" miRNA expression patterns in the blood of patients with Stage 1 to Stage 4 cancer compared to those who were cancer-free.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: weighting scheme increases GWAS power, and more.

Marc Tessier-Lavigne is to be the next president of Stanford University.

Walgreens has given Theranos 30 days to fix its lab issues, the Wall Street Journal reports.

Journals and research funding agencies pledge to enable the sharing of Zika virus research.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.